



Nigel Liverton, PhD

VP of Chemistry

*Talk Title tba*

Nigel Liverton obtained his PhD at Southampton University in the U.K. and following postdoctoral research with Prof. Amos B Smith at the University of Pennsylvania, spent 28 years at UK and US sites for Merck Research Laboratories, where he led multidisciplinary drug discovery teams targeting diseases in the CNS, cardiovascular, immunology and infectious diseases areas. His group was responsible for advancing multiple drug candidates into clinical development. Contributions to the discovery of the HCV protease inhibitor grazoprevir were recognized with a “Heroes of Chemistry” award presented by the American Chemical Society. He subsequently joined WuXi AppTec as Executive Director in the International Discovery Service Unit working with a wide range of clients to advance their small molecule discovery efforts. Currently, as VP of Chemistry at the Tri-Institutional Therapeutics Discovery Institute, Nigel provides scientific leadership across the portfolio of small molecule drug discovery projects to advance research at Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and The Rockefeller University towards small molecule clinical candidates for novel targets.